We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.

Cell | Oct 20, 2016

Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

Pubmed ID: 27768891 RIS Download

Mesh terms: Antibodies, Monoclonal | Antibodies, Neutralizing | Antibodies, Viral | Antibody Specificity | Cowpox | Cowpox virus | Cross Reactions | Humans | Leukocytes, Mononuclear | Monkeypox | Monkeypox virus | Poxviridae Infections | Smallpox | Vaccinia | Vaccinia virus | Variola virus

Research tools detected in this publication

Data used in this publication

None found

Associated grants

  • Agency: NIH HHS, Id: P51 OD011092
  • Agency: NCATS NIH HHS, Id: UL1 TR000445
  • Agency: BLRD VA, Id: I01 BX001444
  • Agency: NIDDK NIH HHS, Id: P30 DK058404
  • Agency: NIAID NIH HHS, Id: U01 AI48512
  • Agency: NIAID NIH HHS, Id: U19 AI109948
  • Agency: NCI NIH HHS, Id: P30 CA068485
  • Agency: NCRR NIH HHS, Id: UL1 RR024975
  • Agency: NIAID NIH HHS, Id: HHSN272200900047C
  • Agency: NIAID NIH HHS, Id: U01 AI048512

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.

GenePix Pro

Industry standard microarray image analysis software because of its unique combination of imaging and analysis tools, visualizations, automation capabilities, performance and intuitive workflows.


View all literature mentions


Tool that predicts interactions between transcription factors and their regulated genes from binding motifs. Understanding vertebrate development requires unraveling the cis-regulatory architecture of gene regulation. PRISM provides accurate genome-wide computational predictions of transcription factor binding sites for the human and mouse genomes, and integrates the predictions with GREAT to provide functional biological context. Together, accurate computational binding site prediction and GREAT produce for each transcription factor: 1. putative binding sites, 2. putative target genes, 3. putative biological roles of the transcription factor, and 4. putative cis-regulatory elements through which the factor regulates each target in each functional role.


View all literature mentions